Pharma Sector: Q2FY24 Review
In Q2FY24, the Pharma Coverage universe posted robust revenue growth of 14.3%/1.7% YoY/QoQ on account of volume rampup, new launches (especially...
304 Views
2023 High Conviction Update: Cipla (CIPLA IN)- Q2 Result Beats Estimates; Margin Guidance Raised
In Q2, Cipla clocked record high quarterly revenue at INR66.8B, up 15% YoY, and EBITDA margin of 26%. The company raised FY24 EBITDA margin...
403 Views
Axis Top Picks - ‘Growth at a Reasonable Price’ – an Overarching Theme - Nov 2023
We are proud to share that our Axis Top Picks basket delivered impressive returns of 25% in the last one year, beating the benchmark Nifty 50 index
213 Views
Dr. Reddy's Laboratories (DRRD IN): Highest Ever Sales and Profit in Q2; Good Show in Key Markets
Revenue increased 9% YoY to INR69B, beating street’s expectation of INRINR68, driven by double-digit growth North America and Europe. Net profit...
330 Views
Pharma - Q2FY24 - Earnings Preview
The Pharma companies under our coverage are likely to report aggregate Revenue/EBITDA/PAT growth of 17.4%/23.8%/25.2% YoY in Q2FY24E.
279 Views